chr10-94775416-T-C
Position:
Variant summary
Our verdict is Likely benign. Variant got -4 ACMG points: 0P and 4B. BS2
The NM_000769.4(CYP2C19):c.358T>C(p.Trp120Arg) variant causes a missense change. The variant allele was found at a frequency of 0.0024 in 1,614,036 control chromosomes in the GnomAD database, including 12 homozygotes. Variant has been reported in ClinVar as drug response (★★★★). Another nucleotide change resulting in same amino acid change has been previously reported as Likely benignin UniProt.
Frequency
Genomes: 𝑓 0.0016 ( 1 hom., cov: 32)
Exomes 𝑓: 0.0025 ( 11 hom. )
Consequence
CYP2C19
NM_000769.4 missense
NM_000769.4 missense
Scores
5
8
5
Clinical Significance
Conservation
PhyloP100: 5.24
Genes affected
CYP2C19 (HGNC:2621): (cytochrome P450 family 2 subfamily C member 19) This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and is known to metabolize many xenobiotics, including the anticonvulsive drug mephenytoin, omeprazole, diazepam and some barbiturates. Polymorphism within this gene is associated with variable ability to metabolize mephenytoin, known as the poor metabolizer and extensive metabolizer phenotypes. The gene is located within a cluster of cytochrome P450 genes on chromosome 10q24. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_benign. Variant got -4 ACMG points.
BS2
High AC in GnomAd4 at 239 AD gene.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
CYP2C19 | NM_000769.4 | c.358T>C | p.Trp120Arg | missense_variant | 3/9 | ENST00000371321.9 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
CYP2C19 | ENST00000371321.9 | c.358T>C | p.Trp120Arg | missense_variant | 3/9 | 1 | NM_000769.4 | P1 | |
CYP2C19 | ENST00000480405.2 | c.358T>C | p.Trp120Arg | missense_variant | 3/3 | 1 | |||
CYP2C19 | ENST00000645461.1 | n.1411T>C | non_coding_transcript_exon_variant | 2/7 |
Frequencies
GnomAD3 genomes AF: 0.00157 AC: 239AN: 152090Hom.: 1 Cov.: 32
GnomAD3 genomes
AF:
AC:
239
AN:
152090
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.00155 AC: 390AN: 251484Hom.: 0 AF XY: 0.00171 AC XY: 232AN XY: 135912
GnomAD3 exomes
AF:
AC:
390
AN:
251484
Hom.:
AF XY:
AC XY:
232
AN XY:
135912
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.00248 AC: 3628AN: 1461828Hom.: 11 Cov.: 31 AF XY: 0.00240 AC XY: 1744AN XY: 727206
GnomAD4 exome
AF:
AC:
3628
AN:
1461828
Hom.:
Cov.:
31
AF XY:
AC XY:
1744
AN XY:
727206
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.00157 AC: 239AN: 152208Hom.: 1 Cov.: 32 AF XY: 0.00152 AC XY: 113AN XY: 74410
GnomAD4 genome
AF:
AC:
239
AN:
152208
Hom.:
Cov.:
32
AF XY:
AC XY:
113
AN XY:
74410
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
TwinsUK
AF:
AC:
12
ALSPAC
AF:
AC:
7
ESP6500AA
AF:
AC:
6
ESP6500EA
AF:
AC:
17
ExAC
AF:
AC:
187
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: drug response
Submissions summary: Other:2
Revision: practice guideline
LINK: link
Submissions by phenotype
not provided Other:1
other, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Dec 28, 2015 | - Variant classified as "other reportable" ??? variant is clinically benign (not associated with disease) but is reported when observed (e.g. pseudodeficiency alleles). |
CYP2C19: no function Other:1
drug response, practice guideline | curation | Clinical Pharmacogenetics Implementation Consortium | - | - Allele function |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
BayesDel_addAF
Benign
T
BayesDel_noAF
Pathogenic
CADD
Uncertain
DANN
Uncertain
DEOGEN2
Uncertain
T;.
Eigen
Uncertain
Eigen_PC
Uncertain
FATHMM_MKL
Uncertain
D
LIST_S2
Benign
T;.
M_CAP
Benign
T
MetaRNN
Uncertain
D;D
MetaSVM
Uncertain
D
MutationTaster
Benign
N
PrimateAI
Benign
T
PROVEAN
Pathogenic
.;D
REVEL
Uncertain
Sift
Pathogenic
.;D
Sift4G
Pathogenic
D;D
Vest4
MutPred
Gain of disorder (P = 3e-04);Gain of disorder (P = 3e-04);
MVP
MPC
0.020
ClinPred
T
GERP RS
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at